3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
12
Diarrhea
5
Rectal Neoplasms
3
Sarcoma, Alveolar Soft Part
2
Ovarian Neoplasms
2
Colorectal Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Short Bowel Syndrome
1
Recurrence
1
Papillomavirus Infections
1
Neoplasms
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Gliosarcoma
1
Glioblastoma
1
Exanthema
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Colitis, Ulcerative
1
Colitis
1
Interventions
Gels
2
Fulvestrant
2
Doxycycline
2
Dapsone
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Provitamins
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
IFL protocol
1
Hydrocortisone
1
Erlotinib Hydrochloride
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Exanthema
×
Loperamide
×
Clear all
NCT07426822
2026-02-24
SAFE-CAP
Yale University
Phase 2
Not yet recruiting
108 enrolled